Figure 4

In vivo efficacy of DDD01034957 in rodent malaria and pharmacokinetic properties in mice. (A) Plasmodium berghei infected mice were treated orally with 50 mg/kg DDD01034957 or 10 mg/kg chloroquine in the 4-day suppression test. DDD01034957 reduced parasitaemia in infected mice whilst chloroquine completely supressed infection. Numbers in brackets indicate the number of mice remaining in the cohort on a particular day (i.e. those that had not reached their humane endpoint). A treatment cohort was ceased when all mice in the cohort had reached their humane endpoint or after 20 days if no malaria parasitaemia or symptoms were observed. Error bars denote SEM. (B) Female BALB/c mice (n = 3) were treated with 50 mg/kg DDD01034957 by intraperitoneal injection and whole blood concentration sampled over time.